Results 151 to 160 of about 42,681 (176)

Polo-like kinase 1 is essential to DNA damage recovery

Leukemia & Lymphoma, 2010
Radiation treatment and chemotherapy can both cause DNA damage to tumor cells. Tumor cells have specific self-protecting mechanisms to escape death. In this study, we explored the effects of polo-like kinase 1 on the DNA damage recovery system in lymphoma cell lines.
Lin, Liu, Min, Zhang, Ping, Zou
openaire   +2 more sources

Molecular interactions of polo-like kinase 1 in human cancers

Journal of Clinical Pathology, 2016
Polo-like kinase 1 (PLK1) is an essential protein in communicating cell-cycle progression and DNA damage. Overexpression of PLK1 has been validated as a marker for poor prognosis in many cancers. PLK1 knockdown decreases the survival of cancer cells. PLK1 is therefore an attractive target for anticancer treatments.
Ng, Wayne T. (S31415), Shin, Joo-Shik (R14280), Roberts, Tara L. (R17471), Wang, Bin (R18019), Lee, Cheok Soon (R13259)   +4 more
openaire   +3 more sources

Switching Polo-like kinase-1 on and off in time and space

Trends in Biochemical Sciences, 2012
Polo-like kinase (Plk)1 executes several essential functions to promote cell division. These functions range from centrosome maturation in late G2 phase to the regulation of cytokinesis, which necessitates precise separation of Plk1-dependent substrate phosphorylation over time.
Wytse, Bruinsma, Jonne A, Raaijmakers, René H, Medema   +2 more
openaire   +2 more sources

Inhibitors of the Polo‐Box Domain of Polo‐Like Kinase 1

ChemBioChem, 2016
AbstractPolo‐like kinase 1 (Plk1), a key player in mitosis, is overexpressed in a wide range of tumor types and has been validated as a target for tumor therapy. In addition to its N‐terminal kinase domain, Plk1 harbors a C‐terminal protein–protein interaction domain, referred to as the polo‐box domain (PBD).
Angela Berg, Thorsten Berg
openaire   +2 more sources

Developing Polo-like Kinase 1 Inhibitors

Future Medicinal Chemistry, 2020
Xufeng Huang, Zhouling Xie, Chenzhong Liao   +2 more
openaire   +2 more sources

Polo‐like kinase‐1 immunoreactivity is associated with metastases in cutaneous melanoma

Journal of Cutaneous Pathology, 2017
BackgroundPolo‐like kinase‐1 (PLK‐1) is one of the key regulators of cell cycle progression. Increased expression of PLK‐1 was observed in several tumor types.MethodsWe immunohistochemically assessed PLK‐1 expression in neoplastic and stromal compartments of 96 cutaneous melanomas, and analyzed associations between PLK‐1 expression and ...
Maciej Kaczorowski, Tomasz Borowiec, Piotr Donizy, Konrad Pagacz, Wojciech Fendler, Artur Lipinski, Agnieszka Halon, Rafal Matkowski   +7 more
openaire   +2 more sources

Targeting polo‐like kinase 1 to treat kidney diseases

Cell Biochemistry and Function
AbstractGlobally, ∼850 million individuals suffer from some form of kidney disease. This staggering figure underscores the importance of continued research and innovation in the field of nephrology to develop effective treatments and improve overall global kidney health.
Hrushikesh Kulkarni, Neha Dagar, Anil Bhanudas Gaikwad   +2 more
openaire   +2 more sources

Polo-like Kinase 1 as an emerging drug target: structure, function and therapeutic implications

Journal of Drug Targeting, 2021
Ilma Shakeel, Neha Basheer, Gulam Mustafa Hasan   +2 more
exaly  

Small-molecule Inhibitors for Targeting polo-like Kinase 1

Future Medicinal Chemistry, 2020
Iryna Kolosenko, Caroline Palm-Apergi
openaire   +2 more sources

Virtual screening of natural compounds as selective inhibitors of polo-like kinase-1 at C-terminal polo box and N-terminal catalytic domain

Journal of Biomolecular Structure and Dynamics, 2022
Femi Olawale, Opeyemi Iwaloye, Olusola Olalekan Elekofehinti   +2 more
exaly